Background. Group A Streptococcus (GAS)-related disease is responsible for high mortality and morbidity in the Pacific region. The high diversity of circulating strains in this region has hindered vaccine development due to apparently low vaccine coverage of type-specific vaccines.
Streptococcus pyogenes (group A Streptococcus [GAS]) is responsible for both mild and severe disease, ranging from pharyngitis and cutaneous infections to invasive infections including streptococcal toxic shock syndrome (STSS), and other complications such as acute rheumatic fever and rheumatic heart disease [1] . Globally, this bacterium is responsible for a mortality of >500 000 deaths per annum, particularly in low-income countries and in the Pacific region [2, 3] .
In New Caledonia (NC), GAS diseases are a major public health concern. The prevalence of rheumatic heart disease was estimated at 9 per 1000 children in 2008-2010 [4] . A previous hospital-based surveillance study of invasive GAS infection conducted in the hospital in Noumea in 2006 observed an incidence of 38 cases per 100 000 inhabitants [5] . This study found a low case fatality rate (CFR) of 3.3%, possibly reflecting the inclusion of cases of mild severity. We therefore decided in this study to use more stringent criteria to define definite and probable GAS invasive infections.
Molecular typing of GAS relies on the sequence of the gene encoding for a surface protein called the M protein [6] . This M protein, encoded by the emm gene, is a major virulence factor of GAS, mainly due to its antiphagocytic properties [7] , and is the only GAS vaccine antigen that has reached phase 2 clinical trials so far [8, 9] . The N-terminal part of the M protein has a variable nucleotide and amino acid sequence, resulting in antigenic diversity, and is the basis for the widely used, nucleotide-based emm-typing scheme [10] . There have been 223 different emm types reported worldwide [11] . Molecular epidemiology studies have shown considerable variation in emm-type distribution at both a country and regional level [12, 13] . The diversity of strains circulating in low-income settings far exceeds that in high-income settings, resulting in the prediction of low coverage of type-specific vaccines. Moreover, the profile of the many emm types recovered from low-income countries differ considerably from one country to another, thereby hindering vaccine development [14] [15] [16] . Pioneering work in the 1950s showed that the presence of type-specific antibodies is responsible for immunity against the homologous emm type [17, 18] . In contrast, no effect on infection by heterologous GAS types was observed with the strains tested in these studies. However, several lines of evidence suggest that the type-specific paradigm might not be directly applicable to the many strains circulating in low-income countries. The preclinical development of a 30-valent vaccine has demonstrated in vitro cross-protection against isolates expressing M proteins not included in the vaccine [19, 20] . This hypothesis of a cross-protection phenomenon was previously proposed for the many emm types circulating in Brazil based on predictive data of M protein complete sequences [21, 22] . Finally, a new emm-cluster typing system that classifies the many GAS emm types into 48 discrete emm clusters containing closely related M proteins that share binding and structural properties has been recently proposed [23] . This emm-cluster system predicts the M protein vaccine antigen content and serves as a framework to investigate the cross-protection phenomenon. Importantly, the emm-cluster system is not in contradiction with the type-specific paradigm, which was essentially based on the small proportion of variants circulating in high-income countries, but proposes a complementary hypothesis for the many variants from low-income settings [23] .
The present study aimed to characterize the clinical and molecular epidemiology of GAS infections in NC using both the emm-typing and emm-cluster systems to evaluate the implications of these data for vaccine coverage.
METHODS

Patient Population
New Caledonia is a French overseas territory in the Pacific. The indigenous Melanesian Kanak community represents 44.6% of the 252 000 inhabitants [24] . Half of the population lives in the capital city of Noumea. There are only 2 hospitals: the hospital in Noumea, which is the major hospital in NC (482 beds), and the hospital in the Northern province (78 beds).
Study Design
Prospective passive surveillance of GAS infections was undertaken from 1 January to 31 December 2012, at the 2 NC hospitals. We identified GAS isolates through 2 laboratories: the laboratory of Insitut Pasteur for the hospital in Noumea and the laboratory of the Northern hospital. There is no other hospital in the island, so our strain collection is likely to be representative of all GAS infections occuring in the hospital where a microbiological sample was collected. Standard demographic data including age, sex, and residence district were recorded along with with clinical information including clinical presentation, comorbid health conditions, site of isolation, complications, and outcome. A single isolate was included per infection.
Case Definitions
Definite invasive disease was defined by the isolation of GAS from a normally sterile site (eg, blood; cerebrospinal, pleural, or peritoneal fluid). Probable invasive disease was defined as an unwell patient with GAS isolated from a nonsterile site who required 1 or more of the following: hospitalization for intravenous antibiotics; surgery; or admission to the intensive care unit (ICU). Streptococcal toxic shock syndrome was defined using previously published criteria [25] . Noninvasive GAS disease was defined as isolation of GAS from a nonsterile site with a clinical syndrome consistent with GAS infection but that did not meet the probable invasive GAS disease case definition.
Microbiology
Identification of GAS was based on β-hemolysis on blood agar, colony morphology, Gram stain, catalase reaction, and positive latex agglutination test (streptococcal grouping kit, Oxoid). All emm typing was performed according to the protocol described by the US Centers for Disease Control and Prevention (CDC) with minor modifications; primers MF2 and MR1 were used when primer 1 and 2 were not successful, as previously described [16] . One new emm sequence was submitted to the CDC streptococcal database and to GenBank (accession number emm 17.3, GenBank KJ191123). The emm clusters were deduced based on the emm-typing results as recently described [23] . M protein 30-valent vaccine coverage data were deduced using previous studies [19, 20] .
Statistical Analysis
Statistical analyses were performed using Stata version 11 software (StataCorp, College Station, Texas). Categorical variables were described as a median and interquartile range (IQR). Incidence rates were calculated using data from the last census in NC [24] . The Simpson reciprocal index (SRI) was used to measure GAS strain diversity [22] , with confidence intervals (CIs) calculated as previously described [26] . The value of this index ranges from 1 to 223 (total number of emm types described so far)-the higher the value, the greater the diversity.
Comparison of Molecular Epidemiology to Previous Studies
The emm-typing and emm-cluster profiles of the present study were compared with those of a prior epidemiological survey of GAS invasive infection conducted in NC 6 years prior [5] . We only included data from the hospital in Noumea because the previous study was restricted to cases from this hospital; both definite and probable invasive infections were included in this comparison. Because the Pacific region is well known to be associated with a high burden of GAS disease and a high number of circulating strains [12, 13, [27] [28] [29] , our data were compared with data obtained from 2 other Pacific countries, Fiji and Australia. The Fijian study included 535 isolates (67 emm types) associated with invasive disease and noninvasive throat and skin GAS infections in 2006 [29] . The Australian study included 334 isolates (38 emm types) recovered from noninvasive throat and skin infection in the Northern Territory in 2007 [28] .
Ethical Approval
The study was approved by the French ethical research committee (Comite de Protection des Personnes Sud-Ouest et Outre mer III; DC 2012/90). Oral consent for participation in the study was obtained from all adult participants and from parents of the included children.
RESULTS
During the 12-month study period, 318 cases of GAS infection were detected through the microbiology laboratories of the 2 hospitals. The majority of the cases were noninvasive (n = 205), followed by definitely invasive (n = 57) and probably invasive (n = 49) ( Table 1 ). The clinical manifestation was not known for 7 patients. The median age of patients with noninvasive infection was 24 years (IQR, , whereas patients with invasive infections (both definitive and probable) were older (median, 39.5 years; IQR, 21-61). The sex ratio (male: female) was 2:1 in both noninvasive and invasive cases (137/ 68 and 73/33, respectively). Seventy-eight percent (n = 248) of the infections were identifed at the main hospital in Noumea, but no significant difference could be observed between the study sites. Among the noninvasive cases, skin and soft tissue infections (SSTIs) were the most common clinical manifestations (90%) ( Table 1 ). The all-ages incidence of noninvasive GAS infection was 83 cases per 100 000, with a peak incidence in patients aged 15-24 years of 145 cases per 100 000 (Figure 1 ). 
Invasive GAS Infection
The all-ages incidence of definite invasive GAS infection was 23 cases per 100 000 population (95% CI, 18-30 cases per 100 000 population), with a peak incidence of 111 per 100 000 in patients aged >65 years ( Figure 1 ). The median age was 54 years (IQR, 27-67 years), and the sex ratio was 1.7:1. Septicemia was the most frequent clinical manifestation (51%), followed by necrotizing fasciitis (16%) and septic arthritis (7%) ( Table 1) . Two cases of STSS were reported. Two cases (4%) were in children aged <1 year (7 months and 10 months, respectively). Of the 57 patients with invasive GAS disease, the outcome was known for 56, and of these, 8 patients died, corresponding to a CFR of 14% (2 septicemia, 2 necrotizing fasciitis, 2 STSS, 1 pneumonia, 1 cellulitis). The median age of patients who died was 61.5 years (IQR, 54-71.5). All patients who died from invasive disease suffered from comorbidities including diabetes, ischemic heart disease, renal disease, and hypertension (Supplementary Table 1 ). Of the 48 surviving patients, 20 required a surgical drainage procedure (43%), 9 were admitted to the ICU (19%), 2 underwent an amputation (4%), and 1 had STSS (2%). The all-ages incidence of probable invasive infection was 20 cases per 100 000 population (95% CI, 15-26), meaning the total incidence of definite and probable invasive GAS disease was 43 per 100 000 (95% CI, 35-52 per 100 000). The peak incidence of probable disease was 40 per 100 000 in those aged 15-24 years. The majority of patients had an SSTI, with 23 patients (47%) diagnosed with cellulitis and a further 22 diagnosed with erysipelas (Table 1) ; of these 45 patients, 32 required surgical drainage and 3 required admission to the ICU. The median age of patients with probable invasive infection was lower than those with definite disease (24 years; IQR, 20-40 years).
Molecular Epidemiology
Forty-seven different emm types were identified among the 318 GAS strains ( Table 2 ). The 5 most frequent emm types (emm76, emm95, emm25, emm1, and emm93) were responsible for 51% of the cases. The diversity index in this strain population was 14.3 (95% CI, 12.2-17.2). Sixteen emm clusters were identified in this collection, with 5 of these emm clusters (E2, E3, M95, D4, and E4) accounting for 73% of the GAS infections (Supplementary Table 2 ). Table 3 shows that the sample size, strain inclusion criteria, number of emm types and emm clusters, and diversity index were highly similar between the 2 NC studies conducted in 2006 and 2012. However, only 30% of the isolates recovered in Noumea in 2012 belonged to an emm type that was present in the same city in 2006 (Supplementary Table 3 ). In contrast, more than two-thirds of the 2012 isolates belonged to an emm cluster present in 2006. Figure 2 shows that less than a third of the isolates (14%-30%) associated with skin infections in 3 Pacific countries (NC, Fiji, and Australia) belonged to an emm type common to all 3 locations, suggesting major differences between these epidemiologic landscapes. However, the analysis of the emm cluster distribution from the same skin infections demonstrated that 70%-84% of the isolates belonged to an emm cluster A-C3 VA 4 (7) 5 (10) 12 (6) 21
Cross-opsonized 4 (7) 4 (8) 27 (13) 35 (10) 
Cross-opsonized 11 (19) 4 (8) 27 (13) 3 (43) 45 (14) (6) 14 (7) 18 (5) emm95 M95 Cross-opsonized 6 (11) 10 (20) 29 (14) 45 (14) emm100 D2 Cross-opsonized 3 (6) 6 (3) common to all 3 countries. The same analysis was undertaken with all isolates (skin, throat, and invasive disease) included in the 3 locations (Supplementary Figure 1) and provided similar results. The emm-cluster analysis therefore allows finding a common point between what previously appeared to be highly different epidemiology in these 3 countries.
M Protein Vaccine Coverage
Based on the emm types included in the 30-valent vaccine, the theoretical protective coverage of this vaccine would be 24.2% (95% CI, 19.5%-28.9%). When including the emm types that have been shown to be cross-opsonized in a rabbit model [19, 20, 23] , the theoretical protective coverage rises to 76.1% (95% CI, 71.4%-80.8%; Table 2 ). Of note, theoretical coverage of the 30-valent vaccine is unknown for 16 emm types because cross-opsonization of these emm types by the vaccine has not yet been tested; these 16 emm types accounted for 65 isolates, suggesting that the potential efficacy of the 30-valent vaccine could be higher than 76.1% if some of those emm types were cross-opsonized. Independent of any current vaccine candidate, our analysis has facilitated the identification of potential vaccine target priorities in the Pacific region. Figure 3 shows that a vaccine that could demonstrate protection against the 10 most frequent emm clusters recovered from these 3 Pacific countries could provide coverage ranging from 83% to 92%.
DISCUSSION
The incidence of invasive GAS disease in New Caledonia is high, with an all-ages incidence of definite disease of 23 cases per 100 000 population and of definite and probable disease of 43 per 100 000. The incidence of definite disease is severalfold higher than that found in North America and Europe (1-6 per 100 000), more than double that of neighboring Fiji (9.9 per 100 000), and equivalent to that observed in Maori and Pacific Islanders in New Zealand [25, 27, [30] [31] [32] [33] [34] [35] . The reason for the high incidence is not entirely clear, but the addition of noninvasive disease data in our report, along with other Pacific data, support the contention that endemic bacterial SSTI contributes to the high burden in younger age groups (<25 years). Bacterial skin infection in these younger age groups also likely contributes to the very high burden of disease in older age groups by favoring transmission of bacteria to vulnerable patients with comorbid medical disease. These findings warrant further investigation into the effect that public health control of bacterial skin disease may have in reducing invasive GAS disease across all ages. The contribution of comorbid conditions such as diabetes to the high incidence and high CFR of invasive GAS disease is well described in both developing and developed country settings [27, 33] . Poorly controlled diabetes is an important public health problem in NC [36] . Although the incidence of definite invasive GAS disease in 2012 (23 per 100 000) was lower than the overall rate found in 2006 (38 per 100 000), the incidence of definite and probable invasive disease combined in 2012 (43 per 100 000) was comparable to the overall 2006 figure [5] . Although this difference may be due to a real reduction in disease incidence, it is more likely due to differences in case definitions; that is, the earlier study likely included cases of probable invasive disease within their total estimate.
It has been nearly 10 years since the circulation of a high diversity of GAS strains in developing countries was first described, initially in India and in Ethiopia [14, 15] . The question of GAS strain diversity has since been assessed in many other countries [16, 20, 28, 29, 37, 38] , has been reviewed systematically [12, 13] , and has stimulated the development of a new type-specific vaccine formulation [19] in an attempt to overcome the issue of poor coverage in low-income settings [8, 39] . The diversity of GAS strains in NC (SRI 14.3) is higher than in the United States, Canada, and Europe but lower than in Ethiopia, India, and Fiji, for which SRI ranged from 27 to 50 [12] .
Importantly, our results show that, based on emm-typing results, 70% of the strains recovered in New Caledonia in 2012 were absent in the same country 6 years prior. This result is clearly different from what is observed in North America where, although some variation occurs on a year-to-year basis, the overall emm type distribution remains stable through short periods of time, with only a limited number of strains responsible for the majority of infections over the last 10 years [34, 37] . The large change in emm-type distribution in NC indicates that vaccine coverage predictions based on emm-typing results must be interpreted with caution in the Pacific region. Such a transformation in emm-type distribution in a relatively short period of time cannot easily be explained by the minimal changes in socioeconomic, political, or medical climate in NC over these 6 years. An alternative hypothesis could be that the high discriminating power of emm typing might result in detecting differences that, in current times and in specific geographic locations, do not have clinical relevance [40] .
When analyzing the NC data, we found that the emm clusters varied little during the same period of time. We previously demonstrated that the emm-cluster typing system correlates with the binding abilities of the many emm types described so far [23] . Importantly, this capacity to bind host ligands is related with the virulence potential of any GAS isolate [7] . Moreover, in comparison with previous typing methods for GAS, the emmcluster typing provides complementary information in terms of M protein sequence homology, structure conservation, and theoretical efficacy of M protein vaccine candidates [23] . It is therefore likely that this typing identifies clinically relevant variations in GAS epidemiology in the Pacific region. Importantly, this new molecular analysis allowed us to identify a common point between the emm types present in Australia, Fiji, and NC; whereas very few similarities could be found among the emm types in these 3 countries, only a limited number of emm clusters were responsible for most of the disease burden. The emm-cluster system could therefore be an important typing tool to identify vaccine antigen priorities. Of note, the emm-cluster allocation is automatically deduced from the emm-typing results [23] . This new typing system does not replace emm typing but rather adds meaningful information to this broadly used typing scheme.
In conclusion, this study confirmed the high disease burden of GAS infections in NC and supports the added value of the emm-cluster typing system to analyze the epidemiology of GAS and to contribute to global GAS vaccine development efforts by informing vaccine formulation.
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